Dimensional Fund Advisors LP Has $586.92 Million Position in Elanco Animal Health Incorporated $ELAN

Dimensional Fund Advisors LP reduced its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 2.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,527,135 shares of the company’s stock after selling 555,410 shares during the period. Dimensional Fund Advisors LP’s holdings in Elanco Animal Health were worth $586,924,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. KBC Group NV increased its position in shares of Elanco Animal Health by 1.8% in the first quarter. KBC Group NV now owns 91,785 shares of the company’s stock valued at $2,196,000 after acquiring an additional 1,639 shares during the last quarter. Swiss National Bank raised its holdings in Elanco Animal Health by 0.4% during the first quarter. Swiss National Bank now owns 983,392 shares of the company’s stock worth $23,533,000 after acquiring an additional 3,800 shares in the last quarter. Jennison Associates LLC boosted its position in Elanco Animal Health by 18.8% during the first quarter. Jennison Associates LLC now owns 3,120,665 shares of the company’s stock valued at $74,678,000 after purchasing an additional 494,216 shares during the last quarter. Dorsey Wright & Associates acquired a new position in Elanco Animal Health during the first quarter valued at approximately $11,314,000. Finally, Bessemer Group Inc. grew its stake in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after purchasing an additional 525 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $25.18 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The stock’s 50 day moving average price is $23.70 and its two-hundred day moving average price is $23.91. The firm has a market capitalization of $12.57 billion, a price-to-earnings ratio of -50.35, a P/E/G ratio of 1.69 and a beta of 1.68. Elanco Animal Health Incorporated has a 12-month low of $13.39 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same period last year, the firm posted $0.37 earnings per share. The business’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on ELAN shares. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. TD Cowen raised their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.55.

Insiders Place Their Bets

In related news, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.